HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nu Skin enters research agreements

This article was originally published in The Rose Sheet

Executive Summary

Direct seller of anti-aging products has entered into research agreements with Stanford University and Madison, Wis.-based LifeGen Technologies to improve its understanding of the genetic basis of aging. In an Oct. 22 release, the firm says its agreement with Stanford "aims to increase the understanding of fundamental aging mechanisms" and includes access to the university's expertise in dermatological clinical trials. The exclusive agreement with LifeGen will "leverage LifeGen's proprietary methods regarding gene expression profiling and pathways affected by aging." The relationships will "help us develop next-generation skin care and nutritional products," says Joseph Chang, Nu Skin chief scientific officer and executive VP of product development. Provo, Utah-based Nu Skin sells its personal-care products - including cosmetics, hair care and fragrances - in 48 international markets through more than 750,000 independent sales representatives. In 2010, it plans to expand its ageLOC anti-aging line with nutritional supplements (1"The Rose Sheet" June 29, 2009)

You may also be interested in...



Nu Skin Secures Future In Genetics Of Aging With LifeGen Acquisition

Nu Skin’s acquisition of LifeGen Technologies for roughly $11.66 million will ensure that the direct seller’s anti-aging business continues to benefit from LifeGen’s research into the genetic basis for aging.

Nu Skin plans ageLOC expansion

Firm plans to extend its ageLOC offering with introduction of "an unmatched daily skin-care system" this October, according to June 22 release. A nutritional supplement will follow in the second half of 2010, Nu Skin says. Galvanic Spa Facial Gels with ageLOC technology, which targets a "source of internal aging [that] is capable of generating free radicals in the epidermis around the clock," launched in fall 2008. Announcement emerges from firm's international sales meeting in Saint Petersburg, Russia. "AgeLOC will not only have significant implications for an aging population that wants to live young, but also for an increasing number of people who are seeking out Nu Skin's business opportunity to supplement or replace their income," company says. With more than 750,000 independent sales reps in 48 international markets, direct seller notes that its distribution program is an "attractive option" for many in the current economy. By 2030, the world's population of people over the age of 60 is expected to double to more than 1 billion, according to Nu Skin, which "believe[s] that ageLOC is unlocking the secret of youth.

Simplified Clinical Trial Transparency Rules To Go Live In The EU In June

A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules. 

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016503

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel